Bioatla announces poster presentations at the 2024 american association for cancer research (aacr) annual meeting

San diego, march 07, 2024 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2024 american association for cancer research (aacr) annual meeting to be held at the san diego convention center in san diego, california from april 5–10, 2024.
BCAB Ratings Summary
BCAB Quant Ranking